Nakamura Y, Sekine I, Furuse K, Saijo N
Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Cancer Chemother Pharmacol. 2000;46(2):114-8. doi: 10.1007/s002800000143.
To evaluate the safety and efficacy of paclitaxel in elderly patients with advanced non-small-cell lung cancer (NSCLC).
We compared the toxicity, response, survival and pharmacokinetic parameters between patients between 70 and 75 years of age (elderly group) and those under 70 years of age (younger group) who were enrolled in two phase II trials of 3-h infusions of paclitaxel.
A total of 120 patients were eligible for the studies, of whom 28 were in the elderly group and 92 in the younger group. Neutropenia was the most prominent toxicity. Grade 3-4 neutropenia was recorded in 89.3% of the elderly group and in 73.9% of the younger group (P = 0.13). Other hematological and non-hematological toxicities were mild regardless of age. Tumor response (46.4% vs 32.2%) and median survival time (9.8 months vs 6.8 months) did not differ between the elderly and younger groups. Pharmacokinetic studies failed to detect any difference between the two groups.
Intravenous 3-h infusions of paclitaxel are as safe and effective in elderly patients with NSCLC as in younger patients.
评估紫杉醇在老年晚期非小细胞肺癌（NSCLC）患者中的安全性和有效性。
我们比较了年龄在70至75岁之间的患者（老年组）和70岁以下的患者（较年轻组）在两项紫杉醇3小时输注的II期试验中的毒性、反应、生存率和药代动力学参数。
共有120名患者符合研究条件，其中28名在老年组，92名在较年轻组。中性粒细胞减少是最突出的毒性。老年组89.3%的患者和较年轻组73.9%的患者出现3-4级中性粒细胞减少（P = 0.13）。无论年龄如何，其他血液学和非血液学毒性均较轻。老年组和较年轻组之间的肿瘤反应（46.4%对32.2%）和中位生存时间（9.8个月对6.8个月）没有差异。药代动力学研究未能检测到两组之间的任何差异。
对于老年NSCLC患者，静脉输注3小时紫杉醇与较年轻患者一样安全有效。
